A year after the FDA found shredded quality documents at an Intas Pharmaceuticals drug manufacturing facility in India, Intas’ parent company Accord Healthcare resumed making cisplatin, which has been in dire shortage for months.
Read the full post on Becker's Hospital Review - Healthcare News
